denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Symposia: ASH-a-Palooza
Program: Trainee Activities and Services
Hematology Disease Topics & Pathways:
Research, Clinical trials, Translational Research, MPN, Clinical Research, Education, Chronic Myeloid Malignancies, Diseases, Real-world evidence, Myeloid Malignancies
Hematology Disease Topics & Pathways:
Research, Clinical trials, Translational Research, MPN, Clinical Research, Education, Chronic Myeloid Malignancies, Diseases, Real-world evidence, Myeloid Malignancies
Friday, December 6, 2024: 1:30 PM-3:50 PM
Café Sevilla Restaurant
(Gaslamp Quarter)
Panelists:
Andres Gomez-De Leon, MD, Universidad Autonoma de Nuevo Leon. Facultad de Medicina y Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
,
Maya Abdallah, MD, Boston University Chobanian and Avedisian School of Medicine and Boston Medical Center
,
Jessica M. Stempel, MD, Yale University
,
Ciara Louise Freeman, PhD, MSc, FRCPC, MRCP, H. Lee Moffitt Cancer Center and Research Institute
,
Ximena Jordan Bruno, MD, University of Pennsylvania
,
Tania Jain, MD, Johns Hopkins University
,
Shruti Chaturvedi, MBBS, Johns Hopkins Hospital
,
Othman S Akhtar, MD, Medical College of Wisconsin
and
Urvi A. Shah, MD, Memorial Sloan Kettering Cancer Center
Disclosures:
Gomez-De Leon: Abbvie: Honoraria; Amgen: Honoraria; bms: Honoraria; Novartis: Honoraria; Pfizer: Honoraria; Janssen: Honoraria; Sanofi: Honoraria, Other: Advisory board; Janssen: Other: Advisory board. Stempel: Sobi: Other: Advisory Board Participation. Freeman: Roche/Genentech: Research Funding; Amgen: Consultancy; Abbvie: Consultancy; Seattle Genetics: Consultancy; Janssen: Consultancy, Research Funding; ONK therapeutics: Consultancy; Celgene: Consultancy; BMS: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy; Incyte: Consultancy. Jain: Bristol Myers Squibb, Incyte, Abbvie, CTI, Kite, Cogent Biosciences, Blueprint Medicine, Telios pharma, Protagonist therapeutics, Galapagos, Tscan therapeutics, Karyopharm, Morphosys: Membership on an entity's Board of Directors or advisory committees; CTI Biopharma, Kartos therapeutics, Incyte, Bristol Myers Squibb: Research Funding. Chaturvedi: SOBI: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; Alexion, AstraZeneca Rare Disease: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees. Akhtar: Sanofi: Honoraria. Shah: Sanofi: Honoraria; Janssen: Honoraria, Research Funding; Bristol Myers Squibb: Research Funding.
Trainees have the opportunity to meet with leaders in the field. Trainees sign up for a one-on-one Blood Buddy ten-minute mentoring session with a faculty member. Blood Buddies are experts in various hematology topic areas. This is an excellent opportunity for trainees to network with and receive mentorship from seasoned faculty. There are 3 Blood Buddies sessions at the event. Although the speakers roles are marked as primary and alternate, multiple speakers may be asked to present on the same topic if that topic will be repeated in the following sets of Blood Buddies. The featured topics are: Adult Clinical Malignant Hematology; Pediatric Clinical Malignant Hematology; Adult Clinical Classical Hematology; Pediatric Clinical Classical Hematology; BMT Pediatric and Adult; Quality Improvement; Medical Education; PhD/Laboratory; Diversity, Equity, and Inclusion; International Medical Graduates; Future of Hematology (Artificial Intelligence); Industry Career Pathway; Federal Career Pathway.